AR and hepatocellular carcinoma: Based upon the existence of constitutively active ligand-independent AR splice variants in HCC and multiple signaling pathways contributing to induced AR expression, effective therapeutic strategies to mitigate AR signaling in HCC will need to focus on targeting the AR itself as opposed to blocking androgen binding or suppressing androgen synthesis.